The judgment of Paris: Treatment dilemmas in advanced renal cell carcinoma

Journal of Clinical Oncology

Volumn 32, Issue 8, 2014, Pages 729-734

  Hwang, Clara ^a   Heath, Elisabeth I ^b  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AXITINIB; BEVACIZUMAB; CALCIUM; CREATININE; EVEROLIMUS; HEMOGLOBIN; INTERFERON; INTERLEUKIN 2; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; ANGIOGENESIS INHIBITOR; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN RECEPTOR;

ADULT; ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CASE REPORT; CELL TYPE; DISEASE FREE INTERVAL; DRUG DOSE INCREASE; FRANCE; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; KIDNEY TUMOR; LABORATORY TEST; LEUKOCYTE; LUNG BIOPSY; LUNG NODULE; LYMPH NODE; MALE; MIDDLE AGED; NEPHRECTOMY; NEUTROPHIL COUNT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT OUTCOME; BIOPSY; CANCER GRADING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG ANTAGONISM; ENZYMOLOGY; FATALITY; LIVER TUMOR; LUNG TUMOR; METABOLISM; METASTASIS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; REVIEW; TIME; TUMOR VOLUME; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; BIOPSY; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; FATAL OUTCOME; HUMANS; INDIVIDUALIZED MEDICINE; KIDNEY NEOPLASMS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; NEPHRECTOMY; PATIENT SELECTION; PROTEIN KINASE INHIBITORS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84899630297     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.6029     Document Type: Article

References (39)

1. American Cancer Society: Cancer Facts and Figures, 2013. http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/ cancer-facts-figures-2013
2. Leibovich BC, Lohse CM, Crispen PL, et al: Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol 183:1309-1315, 2010
3. Teloken PE, Thompson RH, Tickoo SK, et al: Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma. J Urol 182:2132-2136, 2009
4. Eichelberg C, Junker K, Ljungberg B, Moch H: Diagnostic and prognostic molecular markers for renal cell carcinoma: A critical appraisal of the current state of research and clinical applicability. Eur Urol 55:851-863, 2009
5. Cancer Genome Atlas Research Network: Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499:43-49, 2013
6. Motzer RJ, Mazumdar M, Bacik J, et al: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530-2540, 1999 (Pubitemid 29368255)
7. Heng DY, Xie W, Regan MM, et al: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. J Clin Oncol 27:5794-5799, 2009
8. Linehan WM, Srinivasan R, Schmidt LS: The genetic basis of kidney cancer: A metabolic disease. Nat Rev Urol 7:277-285, 2010
9. Linehan WM, Walther MM, Zbar B: The genetic basis of cancer of the kidney. J Urol 170:2163-2172, 2003 (Pubitemid 37413950)
10. Nickerson ML, Jaeger E, Shi Y, et al: Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 14:4726-4734, 2008
11. Escudier B, Bellmunt J, Négrier S, et al: Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival. J Clin Oncol 28:2144-2150, 2010
12. Escudier B, Pluzanska A, Koralewski P, et al: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 370:2103-2111, 2007 (Pubitemid 350296300)
13. Rini BI, Halabi S, Rosenberg JE, et al: Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422-5428, 2008
14. Rini BI, Halabi S, Rosenberg JE, et al: Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206. J Clin Oncol 28:2137-2143, 2010
15. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007 (Pubitemid 46089672)
16. Motzer RJ, Hutson TE, Tomczak P, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584-3590, 2009
17. Sternberg CN, Davis ID, Mardiak J, et al: Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 28:1061-1068, 2010
18. Sternberg CN, Hawkins RE, Wagstaff J, et al: A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. Eur J Cancer 49:1287-1296, 2013
19. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007 (Pubitemid 46089673)
20. Escudier B, Eisen T, Stadler WM, et al: Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312-3318, 2009
21. Hutson TE, Gallardo J, Lesovoy V, et al: Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 31, 2013 (suppl 6s; abstr LBA348)
22. Motzer RJ, Nosov D, Eisen T, et al: Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: Results from a phase III trial. J Clin Oncol 31:3791-3799, 2013
23. Motzer RJ, Hutson TE, Cella D, et al: Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369:722-731, 2013
24. Escudier BJ, Porta C, Bono P, et al: Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC) - PISCES study, NCT 01064310. J Clin Oncol 30:277s, 2012 (abstr CRA4502)
25. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281, 2007 (Pubitemid 46849157)
26. Rini BI, Bellmunt J, Clancy J, et al: Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol 32:752-759, 2014
27. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456, 2008
28. Motzer RJ, Escudier B, Oudard S, et al: Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 116:4256-4265, 2010
29. Rini BI, Escudier B, Tomczak P, et al: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet 378:1931-1939, 2011
30. Motzer RJ, Escudier B, Tomczak P, et al: Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 14:552-562, 2013
31. Hutson TE, Escudier B, Esteban E, et al: Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol [epub ahead of print on December 2, 2013]
32. National Comprehensive Cancer Network guidelines: Kidney cancer, v. 1.2013. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
33. Kavolius JP, Mastorakos DP, Pavlovich C, et al: Resection of metastatic renal cell carcinoma. J Clin Oncol 16:2261-2266, 1998 (Pubitemid 28265066)
34. Fyfe G, Fisher RI, Rosenberg SA, et al: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688-696, 1995
35. Klapper JA, Downey SG, Smith FO, et al: Highdose interleukin-2 for the treatment of metastatic renal cell carcinoma: A retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 113:293-301, 2008
36. Patel PH, Senico PL, Curiel RE, et al: Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 7:24-27, 2009
37. Feldman DR, Baum MS, Ginsberg MS, et al: Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 27:1432-1439, 2009
38. McDermott DF, Manola J, Pins M, et al: The BEST trial (E2804): A randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC). J Clin Oncol 31, 2013 (suppl 6s; abstr 345)
39. Negrier S, Gravis G, Perol D, et al: Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): A randomised phase 2 trial. Lancet Oncol 12:673-680, 2011